Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation (vol 109, pg 1149, 2024)

被引：0

作者：

Epstein-Peterson, Zachary D. ^{[1
]}

Drill, Esther ^{[2
]}

Aypar, Umut ^{[3
]}

Batlevi, Connie Lee ^{[1
]}

Caron, Philip ^{[1
]}

Dogan, Ahmet

Drullinsky, Pamela ^{[1
]}

Gerecitano, John ^{[1
,6
]}

Hamlin, Paul A. ^{[1
]}

Ho, Caleb ^{[3
,7
]}

Jacob, Allison ^{[4
]}

Joseph, Ashlee ^{[1
]}

Laraque, Leana ^{[1
]}

Matasar, Matthew J. ^{[1
]}

Moskowitz, Alison J. ^{[1
]}

Moskowitz, Craig H. ^{[1
,9
]}

Mullins, Chelsea ^{[4
,8
]}

Owens, Colette ^{[1
]}

Salles, Gilles ^{[1
]}

Schoder, Heiko ^{[5
]}

Straus, David J. ^{[1
]}

Younes, Anas ^{[1
,10
]}

Zelenetz, Andrew D. ^{[1
]}

Kumar, Anita ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, Div Hematol Malignancies, New York, NY 10065 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA

[4] Adapt Biotechnol, Seattle, WA USA

[5] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY USA

[6] Janssen Pharmaceut Co Johnson & Johnson, Raritan, NJ USA

[7] Loxo Oncol Inc, Stamford, CT USA

[8] Notch Therapeut, Seattle, WA USA

[9] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med, Div Hematol,Miller Sch Med, Miami, FL USA

[10] AstraZeneca Pharmaceut LP, Wilmington, DE USA

来源：

HAEMATOLOGICA | 2024年 / 109卷 / 08期

关键词：

D O I：

10.3324/haematol.2024.285845

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 30 条

[1] Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
Epstein-Peterson, Zachary D.
Drill, Esther
Aypar, Umut
Batlevi, Connie Lee
Caron, Philip
Dogan, Ahmet
Drullinsky, Pamela
Gerecitano, John
Hamlin, Paul A.
Ho, Caleb
Jacob, Allison
Joseph, Ashlee
Laraque, Leana
Matasar, Matthew J.
Moskowitz, Alison J.
Moskowitz, Craig H.
Mullins, Chelsea
Owens, Colette
Salles, Gilles
Schoeder, Heiko
Straus, David J.
Younes, Anas
Zelenetz, Andrew D.
Kumar, Anita
HAEMATOLOGICA, 2024, 109 (04) : 1149 - 1162
[2] Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
Epstein-Peterson, Zachary D.
Drill, Esther
Aypar, Umut
Batlevi, Connie Lee
Caron, Philip
Dogan, Ahmet
Drullinsky, Pamela
Gerecitano, John
Hamlin, Paul A.
Ho, Caleb
Jacob, Allison
Joseph, Ashlee
Laraque, Leana
Matasar, Matthew J.
Moskowitz, Alison J.
Moskowitz, Craig H.
Mullins, Chelsea
Owens, Colette
Salles, Gilles
Schoder, Heiko
Straus, David J.
Younes, Anas
Zelenetz, Andrew D.
Kumar, Anita
REVISTA CHILENA DE LITERATURA, 2024, (109): : 1149 - 1162
[3] Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard risk acute myeloid leukemia (vol 109, pg 740, 2024)
Maurer-Granofszky, Margarita
Koehrer, Stefan
Fischer, Susanna
Schumich, Angela
Nebral, Karin
Larghero, Patrizia
Meyer, Claus
Mecklenbraeuker, Astrid
Muehlegger, Nora
Marschalek, Rolf
Haas, Oskar A.
Panzer-Gruemayer, Renate
Dworzak, Michael N.
HAEMATOLOGICA, 2024, 109 (07) : 2379 - 2381
[4] Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard risk acute myeloid leukemia (vol 109, pg 740, 2024)
Maurer-Granofszky, Margarita
Koehrer, Stefan
Fischer, Susanna
Schumich, Angela
Nebral, Karin
Larghero, Patrizia
Meyer, Claus
Mecklenbraeuker, Astrid
Muehlegger, Nora
Marschalek, Rolf
Haas, Oskar A.
Panzer-Gruemayer, Renate
Dworzak, Michael N.
REVISTA CHILENA DE LITERATURA, 2024, (109): : 2379 - 2381
[5] Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study
Epstein-Peterson, Zachary D.
Batlevi, Connie Lee
Caron, Philip
Dogan, Ahmet
Drullinsky, Pamela
Gerecitano, John
Hamilton, Audrey
Hamlin, Paul A.
Ho, Caleb
Jacob, Allison P.
Laraque, Leana
Matasar, Matthew J.
Moskowitz, Alison J.
Moskowitz, Craig H.
Mullins, Chelsea D.
Owens, Colette
Salles, Gilles
Schoder, Heiko
Straus, David J.
Younes, Anas
Zelenetz, Andrew D.
Kumar, Anita
BLOOD, 2020, 136
[6] Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)
Gabriel Scheubeck
Linmiao Jiang
Olivier Hermine
Hanneke C. Kluin-Nelemans
Christian Schmidt
Michael Unterhalt
Andreas Rosenwald
Wolfram Klapper
Andrea Evangelista
Marco Ladetto
Mats Jerkeman
Simone Ferrero
Martin Dreyling
Eva Hoster
Leukemia, 2023, 37 : 1887 - 1894
[7] Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)
Scheubeck, Gabriel
Jiang, Linmiao
Hermine, Olivier
Kluin-Nelemans, Hanneke C.
Schmidt, Christian
Unterhalt, Michael
Rosenwald, Andreas
Klapper, Wolfram
Evangelista, Andrea
Ladetto, Marco
Jerkeman, Mats
Ferrero, Simone
Dreyling, Martin
Hoster, Eva
LEUKEMIA, 2023, 37 (9) : 1887 - 1894
[8] Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study
Hudson, Kathryn E.
Rizzieri, David
Thomas, Samantha M.
LeBlanc, Thomas W.
Powell, Zachary
Diehl, Louis
Moore, Joseph O.
DeCastro, Carlos
Beaven, Anne W.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (04) : 647 - 650
[9] Minimal Disseminated Disease in High-Risk Burkitt's Lymphoma Identifies Patients With Different Prognosis (vol 29, pg 1779, 2011)
Mussolin
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1991 - 1991
[10] Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia
Locatelli, Franco
Eckert, Cornelia
Hrusak, Ondrej
Buldini, Barbara
Sartor, Mary
Zugmaier, Gerhard
Zeng, Yi
Pilankar, Deepali
Morris, Joan
von Stackelberg, Arend
PEDIATRIC BLOOD & CANCER, 2022, 69 (08)

← 1 2 3 →